8 September 2020 - Comprehensive pan-tumour liquid biopsy test analyzes >300 cancer-associated genes and multiple genomic signatures to inform treatment choices.

Hoffmann-La Roche Limited (Roche Canada) today announced that FoundationOne Liquid CDx, Foundation Medicine's comprehensive pan-tumour liquid biopsy test for patients with solid tumours, is now available in Canada.

FoundationOne Liquid CDx is a comprehensive genomic profiling test that analyzes >300 cancer-associated genes and multiple genomic signatures to inform the use of targeted oncology therapies, including immunotherapies.

Read Roche press release